Results 11 to 20 of about 16,658,609 (280)
International Journal of Molecular Sciences, 2020 CAR-T therapy has revolutionized the treatment of select hematological malignancies, namely, acute lymphoblastic leukemia and large B-cell lymphomas [...]
Aamir Ahmad
openaire +3 more sources
Cancer Stem Cell as Target of CAR-T Cell Therapy [PDF]
E3S Web of Conferences, 2020 Chimeric antigen receptor-T cell (CAR-T) therapy has been studied intensively these years and is considered a promising cancer treatment. So far, Food and Drug Administration has approved 2 CAR-T cell therapy for patients with refractory leukemia and the
Li Xinran
doaj +2 more sources
CAR-T Cell Therapy and the Gut Microbiota
Cancers, 2023 Chimeric antigen receptor (CAR) - T cell cancer therapy has yielded promising results in treating hematologic malignancies in clinical studies, and a growing number of CAR-T regimens are approved for clinical usage. While the therapy is considered of great potential in expanding the cancer immunotherapy arsenal, more than half of patients receiving CAR-
Sahana Asokan +3 more
openaire +3 more sources
Advances in CAR-T-cell therapy in T-cell malignancies
Journal of Hematology & OncologySignificant advances have been made in chimeric antigen receptor T (CAR-T)-cell therapy for the treatment of recurrent or refractory B-cell hematologic malignancies. However, CAR-T-cell therapy has not yet achieved comparable success in the management of
Rubing Zheng, Xiaojian Zhu, Yi Xiao
doaj +2 more sources
Advances in chimeric antigen receptor T-cell therapy for B-cell non-Hodgkin lymphoma
Biomarker Research, 2021 B-cell non-Hodgkin lymphoma (B-NHL) is a group of heterogeneous disease which remains incurable despite developments of standard chemotherapy regimens and new therapeutic agents in decades.
Zixun Yin, Ya Zhang, Xin Wang
doaj +1 more source
Hematology/Oncology and Stem Cell Therapy, 2022 Chimeric antigen receptor T-cell (CAR T-cell) therapy represents an innovative and transformative therapy for patients with relapsed and/or refractory (R/R) hematological malignancies.
Farah Yassine +4 more
doaj +1 more source
Frontiers in Oncology, 2021 CAR T-cell therapy has revolutionized the treatment approach to patients with relapsed/refractory hematologic malignancies; however, there continues to be opportunity for improvement in treatment toxicity as well as response durability. Radiation therapy
Penny Q. Fang +7 more
doaj +1 more source
Revealing Facts About CAR-T Cell Therapy [PDF]
ImmunoAnalysis, 2022 Chimeric antigen receptor (CAR)-T cell therapy is a fast-emerging treatment for several types of cancers and has several applications beyond oncology. It is a new emerging treatment targeting for a broad range of cancers.
Daggupati Sai Padmanjali +2 more
doaj +1 more source
CAR-T Cell Therapy for Lymphoma [PDF]
Annual Review of Medicine, 2016 Lymphomas arise from clonal expansions of B, T, or NK cells at different stages of differentiation. Because they occur in the immunocyte-rich lymphoid tissues, they are easily accessible to antibodies and cell-based immunotherapy. Expressing chimeric antigen receptors (CARs) on T cells is a means of combining the antigen-binding site of a monoclonal ...
Carlos A, Ramos +2 more
openaire +2 more sources
The landscape of chimeric antigen receptor T cell therapy in breast cancer: Perspectives and outlook
Frontiers in Immunology, 2022 Chimeric antigen receptor-T (CAR-T) cell therapy is a revolutionary adoptive cell therapy, which could modify and redirect T cells to specific tumor cells.
Hao Zhang +5 more
doaj +1 more source